Combination Chemotherapy With Doxorubicin and Lomustine

ABDIC was administered to 32 patients with MOPP-resistant Hodgkin's disease. Three were considered nonevaluable because of early death. All patients had received MOPP (medium of eight cycles), and five had also received other chemotherapy. Major radiotherapy had been used in 18 of the 29. Complete remission (CR) occurred in 10 of 29 (34.5%), partial remissions (PR) in 14 (48.2%), and no remissions (NR) in five (17.2%). Median survival and relapse-free survival for CR patients exceeded 28 months. Two relapsed at 8 and 18 months; one died at 9 1/2 months, and the other is disease-free with other treatment at 35 months. Seven of the remaining eight patients are alive without disease (10-35 months); 4 are on maintenance therapy, and the other died from an infection and eosinophilic granuloma of lung without evidence of recurrent Hodgkin's disease. Median survival of PR patients was eight months. One patient with Hodgkin's disease involving the liver is alive at 36 months with further therapy. Median survival of NR patients is 2.5 months, and all died within seven months. Survival of CR patients is greater than PR and NR patients (P = 0.002), and that of PR is greater than NR (P = 0.01). Four of the 29 patients had nodal relapse, and 25 had parenchymal relapse, with no difference in response rates (P = 0.47). ABDIC is useful in Hodgkin's disease patients who have had extensive prior chemotherapy and radiotherapy.

Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease

Rodgers¹,

Gamble²,

Loh³

et al. 1980

The superiority of CCNU in the treatment of advanced hodgkin's disease: Cancer and leukemia group b study

Hansen¹,

Selawry

Pajak

et al. 1981

In a randomized study, the effect of single agent therapy, with CCNU was compared with that of BCNU in previously treated patients with advanced Hodgkin's disease. The dosage of CCNU was 100 mg/m2 p.o. q. 6 weeks and of BCNU, 200 mg/m2, p. 6 weeks with dose modification adjusted to individual tolerance. For 60 evaluable patients the response rate (complete and partial was 60 for CCNU and 28% for BCNU (p = 0.025); median duration of response was 4.5 months and 2.0 months, respectively (P = 0.26). Median survival for responders was 11.0 months and for non-responders 5.0 months. No major difference was observed in hematologic toxicity between the two compounds. Used as single agents in equitoxic dosages, CCNU is superior to BCNU for the treatment of previously treated advanced Hodgkin's disease, and CCNU has the additional advantage of oral administration.

Treatment of advanced untreated Hodgkin's disease with SCAB—an alternative to MOPP

Diggs

Wiernik

Sutherland

1981

SCAB chemotherapy streptozocin (streptozotocin) lomustine (CCNU), doxorubicin hydrochloride (Adriamycin), and bleomycin sulfate was given in monthly courses to 20 patients with Stages IIIB, IVA, and IVB previously untreated Hodgkin's disease. Complete remissions were obtained in 15 (75%) of these patients, and partial remissions in two others. Toxicity of this program was acceptable. Although this study was not a direct comparison with MOPP, SCAB would appear to be at least as effective as MOPP and offers a reasonable alternative program for the patient with advanced stage, previously untreated Hodgkin's disease.